Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life.
Nagot N, Singata-Madliki M, Cournil A, Nalugya J, Tassembedo S, Quillet C, Tonga MW, Tumwine J, Meda N, Kankasa C, Mwiya M, Bangirana P, Peries M, Batting J, Engebretsen IMS, Tylleskär T, Perre PV, Ndeezi G, Molès JP.
Nagot N, et al. Among authors: bangirana p.
Sci Rep. 2021 Feb 4;11(1):3173. doi: 10.1038/s41598-021-82762-8.
Sci Rep. 2021.
PMID: 33542437
Free PMC article.
Clinical Trial.